• News

"Efficacy, Safety of Psoriasis Drug Taltz Sustained Over Four Years" - Alaina Tedesco

  • Healio: Primary Care Today
  • New York, NY
  • (April 05, 2019)

Taltz demonstrated high levels of efficacy and safety for the treatment of psoriasis over four years, according to research presented at the American Academy of Dermatology Annual Meeting. “Taltz, a high-affinity monoclonal antibody that selectively targets IL-17A, has shown sustained high efficacy response over three years with consistent safety profile in moderate-to-severe psoriasis patients,” said Mark Lebwohl, MD, chair of the department of dermatology at the Mount Sinai Health System who authored the study. Dr. Lebwohl added, “High efficacy response was demonstrated with ixekizumab treatment that sustained over 4 years in patients with moderate-to-severe plaque psoriasis. The safety profile remained consistent with prior findings, with no or unexpected new safety concerns.” 

— Mark G. Lebwohl, MD, Professor, Dermatology, Icahn School of Medicine at Mount Sinai, Chair, Waldman Department of Dermatology, Mount Sinai Health System

Learn more